VITAL THERAPIES, INC. (NASDAQ:VTL) Files An 8-K Results of Operations and Financial Condition
Item 9.01
Results of Operations and Financial Condition.
On March 4, 2019, Vital Therapies, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2018. In its press release, the Company also provided a corporate update. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Item 9.01, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this current report shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, whether filed before or after the date hereof regardless of any general incorporation language in any such filing, unless the registrant expressly sets forth in such filing that such information is to be considered “filed” or incorporated by reference therein.
|
Item 9.01. |
Financial Statements and Exhibits. |
|
Exhibit |
Description |
|
99.1 |
Press Release, dated March 4, 2019.
|
VITAL THERAPIES INC Exhibit
EX-99.1 2 vtlq42018prfinal.htm EXHIBIT 99.1 Exhibit VITAL THERAPIES ANNOUNCES 2018 FINANCIAL RESULTS EXHIBIT 99.1SAN DIEGO,…
To view the full exhibit click here
About VITAL THERAPIES, INC. (NASDAQ:VTL)
Vital Therapies, Inc. is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant. The ELAD System is a liver support system containing immortal human liver-derived cells, or VTL C3A cells. The Company initiated a Phase III clinical trial in severe acute alcoholic hepatitis (sAAH), referred to as VTL-308. Its VTL-308 is a randomized, open-label, multicenter, controlled, pivotal study, designed to evaluate the ELAD System in subjects with sAAH. It is based on pre-specified and post-hoc analyses of its VTI-208 phase III clinical trial in alcohol-induced liver decompensation (AILD). The Company’s ELAD System consists of approximately four disposable ELAD C3A cell cartridges.
